Ethics, Stewardship, and Laboratory Tests of Unproven Benefit - - PowerPoint PPT Presentation

ethics stewardship and laboratory tests of unproven
SMART_READER_LITE
LIVE PREVIEW

Ethics, Stewardship, and Laboratory Tests of Unproven Benefit - - PowerPoint PPT Presentation

Ethics, Stewardship, and Laboratory Tests of Unproven Benefit Brian Jackson, MD, MS Assoc Prof of Pathology (Clinical), University of Utah Medical Director, IT and Support Services, ARUP Laboratories Cas Case: e: Neo eopt pterin erin Tes


slide-1
SLIDE 1

Ethics, Stewardship, and Laboratory Tests of Unproven Benefit

Brian Jackson, MD, MS

Assoc Prof of Pathology (Clinical), University of Utah Medical Director, IT and Support Services, ARUP Laboratories

slide-2
SLIDE 2

Cas Case: e: Neo eopt pterin erin Tes est O Orders rders

  • Biomarker that correlates with T-cell activity
  • Of research interest, but not in mainstream clinical

use for any particular disease

  • 770 orders to ARUP over a 12 month period

– 83% from a single hospital – 64% of those were placed by a single physician (=53% of ARUP’s national volume)

slide-3
SLIDE 3

When is it appropriate for clinicians to order tests of unproven/uncertain clinical utility?

slide-4
SLIDE 4

Definitions

  • Analytic validity = accuracy in measuring a

biomarker

  • Clinical validity = accuracy in

diagnosing/assessing a disease

  • Clinical utility = medical benefit to the patient
slide-5
SLIDE 5

Examples of unproven clinical utility

  • Tests that don’t distinguish clearly between

disease and non-disease

  • Tests that tell us what we already know
  • Tests that tell us something we don’t need
  • Tests that have not been well studied in a

particular clinical setting

slide-6
SLIDE 6

What’s the best lens through which to view this issue?

slide-7
SLIDE 7

Political Ethics Science FDA

$

slide-8
SLIDE 8

Laboratory Testing Stakeholders

Regulators Clinical Laboratories Physicians Hospitals Payers Patients

slide-9
SLIDE 9

Laboratory Testing Stakeholders

Regulators Clinical Laboratories Physicians Hospitals Payers Patients

Ethics

slide-10
SLIDE 10

Definitive Statements of Bioethics

Declaration of Geneva (Individual Physician) Belmont Report (Researcher)

slide-11
SLIDE 11

Declaration of Geneva

  • Physician perspective

– Patients come first – Confidentiality – Good medical practice – Advance the profession – Advance the science

slide-12
SLIDE 12

Belmont Report

  • (Human subjects) researcher perspective

– Respect for persons – Beneficence – Justice

slide-13
SLIDE 13

Applying these principles to laboratory testing…

slide-14
SLIDE 14

Beneficience and Nonmaleficence

  • Benefit to patient = clinical utility
  • Potential harm to patient?

– Should always be considered a possibility

slide-15
SLIDE 15

Respect for Autonomy and Dignity of Patients

  • Informed consent

– Fully informed decisionmaking requires information regarding risks and benefits

slide-16
SLIDE 16

“Good Medical Practice”

  • Includes:

– Guidelines – Evidence-based medicine – Generally accepted practices

  • Does not include personal preferences or ideas
slide-17
SLIDE 17

Advancing the Science

  • Fill gaps in medical knowledge
  • Sound research methods

– Controlled prospective trials where practical – Retrospective analyses that control for bias – Large enough sample sizes to draw significance

slide-18
SLIDE 18

Justice

  • Healthcare resources are limited

– Should be spent where they can provide the most benefit

slide-19
SLIDE 19

Tests of unproven clinical utility raise multiple ethical challenges

  • Benefit is uncertain
  • Harm can’t be ruled out
  • Fully informed consent is problematic
  • Lack of external guidance
  • One-off testing doesn’t advance the science
  • Often expensive
slide-20
SLIDE 20

What’s the most ethical approach to these tests?

slide-21
SLIDE 21

Research paradigm for emerging tests

  • Formal study protocols

– Could include registries/retrospective analyses – IRB oversight – Informed consent = acknowledge what we don’t know

slide-22
SLIDE 22

Research paradigm for emerging tests

  • Compassionate Use

– Clinical judgment has a legitimate role – Unique patients may benefit from unique approaches

  • But unique doctors might need to be reined in

– Institutional oversight

slide-23
SLIDE 23

Research paradigm for emerging tests

  • Funding

– Public/private, grants/contracts – Self-pay – Not health insurance

slide-24
SLIDE 24

Summary

  • Tests of uncertain clinical utility should follow a

research paradigm, not a marketing paradigm

– Protect patients – Advance the science – Protect resources